BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11800029)

  • 1. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
    Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
    Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
    Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
    Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
    Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
    Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K
    Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
    Fukuda M; Oka M; Soda H; Terashi K; Kawabata S; Nakatomi K; Takatani H; Tsurutani J; Tsukamoto K; Noguchi Y; Fukuda M; Kinoshita A; Kohno S
    Clin Cancer Res; 1999 Dec; 5(12):3963-9. PubMed ID: 10632326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
    Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
    Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
    Takeda K; Negoro S; Takifuji N; Nitta T; Yoshimura N; Terakawa K; Fukuoka M
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):104-8. PubMed ID: 11561775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based maximum tolerated dose of irinotecan and carboplatin.
    Wild CA; Wang SE; Gandara DR; Lara PN; Meyers FJ; Tanaka M; Houston J; Lauder J; Lau DH
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):11-6. PubMed ID: 12886868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Anticancer Drugs; 2000 Nov; 11(10):821-4. PubMed ID: 11142689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
    Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
    Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
    Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
    Natale RB; Socinski M; Sandler A; Israel VP; Miller L
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.